- Home
- CTO vs KROS Comparison
CTO vs KROS Comparison
Compare CTO & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | KROS |
|---|---|---|
| Founded | 1902 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 552.9M | 565.0M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CTO | KROS |
|---|---|---|
| Price | $17.82 | $21.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 15 |
| Target Price | $22.00 | ★ $22.20 |
| AVG Volume (30 Days) | 254.1K | ★ 1.1M |
| Earning Date | 10-28-2025 | 11-05-2025 |
| Dividend Yield | ★ 8.55% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.57 |
| Revenue | $146,948,000.00 | ★ $246,718,000.00 |
| Revenue This Year | $20.87 | $6,876.34 |
| Revenue Next Year | $4.29 | N/A |
| P/E Ratio | ★ N/A | $13.66 |
| Revenue Growth | 23.84 | ★ 37798.31 |
| 52 Week Low | $15.07 | $9.12 |
| 52 Week High | $20.88 | $22.55 |
Technical Indicators
Market Signals| Indicator | CTO | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 55.39 | 75.04 |
| Support Level | $17.81 | $20.78 |
| Resistance Level | $18.31 | $22.20 |
| Average True Range (ATR) | 0.25 | 0.97 |
| MACD | -0.06 | 0.35 |
| Stochastic Oscillator | 39.72 | 83.47 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.